See every side of every news story

Published 2 days ago • loading... • Updated 2 days ago

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Summary by PR Newswire

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society...

10 Articles

10 Articles

Farm Talk Newspaper

+8 Reposted by 8 other sources

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers.

2 days ago·Parsons, United States

Read Full Article

The Huntsville Item

Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 13, 2025-

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources10

Leaning Left1Leaning Right0Center4Last Updated1 day agoBias Distribution

80% Center

Bias Distribution

80% of the sources are Center

80% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Huntsville Item broke the news in 2 days ago on Monday, October 13, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics